Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for…
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for…